These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31232394)

  • 21. Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
    Selby R; Kaus L; Sealey F; Koo M; Parpia S; Chan B; Seung SJ; Bradley C; Strauss R; Mittmann N
    PLoS One; 2023; 18(4):e0284425. PubMed ID: 37071625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.
    Chung JE; Choi YR; Seong JM; La HO; Gwak HS
    Int J Clin Pharm; 2015 Dec; 37(6):1038-46. PubMed ID: 26068570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Dysfunction Affects Anticoagulation Control With Warfarin and Outcomes in Japanese Elderly Patients With Non-Valvular Atrial Fibrillation.
    Inoue H; Kodani E; Atarashi H; Okumura K; Yamashita T; Origasa H;
    Circ J; 2018 Aug; 82(9):2277-2283. PubMed ID: 29984788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry.
    Wang C; Yang Z; Wang C; Wang Y; Zhao X; Liu L; Wang DZ; Li H; Wang Y
    J Stroke Cerebrovasc Dis; 2014; 23(5):1157-63. PubMed ID: 24291013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do anticoagulated atrial fibrillation patients who suffer ischemic stroke or spontaneous intracerebral hemorrhage differ?
    Lehtola H; Hartikainen J; Hartikainen P; Kiviniemi T; Nuotio I; Palomäki A; Ylitalo A; Airaksinen KEJ; Mustonen P
    Clin Cardiol; 2018 May; 41(5):608-614. PubMed ID: 29745996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.
    Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):205-11. PubMed ID: 25944648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
    JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry.
    Lehto M; Niiranen J; Korhonen P; Mehtälä J; Khanfir H; Hoti F; Lassila R; Raatikainen P
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):657-665. PubMed ID: 28317274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation.
    Chan YH; Lee KT; Kao YW; Huang CY; Chen YL; Hang SC; Chu PH
    PLoS One; 2019; 14(3):e0213517. PubMed ID: 30883567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management.
    Bahbahani H; AlTurki A; Dawas A; Lipman ML
    BMC Nephrol; 2018 Jan; 19(1):4. PubMed ID: 29310600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation.
    Krittayaphong R; Winijkul A; Pirapatdit A; Chiewvit P; Komoltri C; Boonyapisit W; Arunsiriwattana S; Bunyapipat T; Apiyasawat S; Rattanasumawong K; Yindeengam A;
    Singapore Med J; 2020 Dec; 61(12):641-646. PubMed ID: 31680175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.
    Marcatto LR; Sacilotto L; Bueno CT; Facin M; Strunz CM; Darrieux FC; Scanavacca MI; Krieger JE; Pereira AC; Santos PC
    BMC Cardiovasc Disord; 2016 Nov; 16(1):224. PubMed ID: 27855643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficiency and safety of anticoagulation therapy in atrial fibrillation in Chinese].
    Sun YH; Hu DY
    Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):258-60. PubMed ID: 15130407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International Normalized Ratio Variability: A Measure of Anticoagulation Quality or a Powerful Mortality Predictor.
    Vanerio G
    J Stroke Cerebrovasc Dis; 2015 Oct; 24(10):2223-8. PubMed ID: 26232891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
    Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
    Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with therapeutic anticoagulation status in patients with ischemic stroke and atrial fibrillation.
    Yaghi S; Liberman AL; Henninger N; Grory BM; Nouh A; Scher E; Giles J; Liu A; Nagy M; Kaushal A; Azher I; Fakhri H; Espaillat KB; Asad SD; Pasupuleti H; Martin H; Tan J; Veerasamy M; Esenwa C; Cheng N; Moncrieffe K; Moeini-Naghani I; Siddu M; Trivedi T; Ishida K; Frontera J; Lord A; Furie K; Keyrouz S; de Havenon A; Mistry E; Leon Guerrero CR; Khan M
    J Stroke Cerebrovasc Dis; 2020 Jul; 29(7):104888. PubMed ID: 32414583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.